array:24 [
  "pii" => "S0001731017305604"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2017.07.019"
  "estado" => "S300"
  "fechaPublicacion" => "2018-07-01"
  "aid" => "1826"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2017"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "crp"
  "cita" => "Actas Dermosifiliogr. 2018;109:565-7"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 83
    "formatos" => array:2 [
      "HTML" => 43
      "PDF" => 40
    ]
  ]
  "Traduccion" => array:1 [
    "en" => array:19 [
      "pii" => "S1578219018301628"
      "issn" => "15782190"
      "doi" => "10.1016/j.adengl.2018.05.005"
      "estado" => "S300"
      "fechaPublicacion" => "2018-07-01"
      "aid" => "1826"
      "copyright" => "Elsevier España, S.L.U. and AEDV"
      "documento" => "simple-article"
      "crossmark" => 1
      "subdocumento" => "crp"
      "cita" => "Actas Dermosifiliogr. 2018;109:565-7"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 14
        "formatos" => array:2 [
          "HTML" => 8
          "PDF" => 6
        ]
      ]
      "en" => array:11 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>"
        "titulo" => "Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "565"
            "paginaFinal" => "567"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Respuesta a secukinumab tras fracaso terap&#233;utico con ustekinumab en seis pacientes con psoriasis en placas"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figure 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 828
                "Ancho" => 2185
                "Tamanyo" => 151810
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Response to treatment with secukinumab in patients with an unacceptable response to treatment with ustekinumab&#46;PASI&#44; Psoriasis Area and Severity Index&#59; SEC&#44; secukinumab&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "D&#46; Morgado-Carrasco, J&#46; Riera-Monroig, X&#46; Fust&#224;-Novell, M&#46; Alsina Gibert"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Morgado-Carrasco"
              ]
              1 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Riera-Monroig"
              ]
              2 => array:2 [
                "nombre" => "X&#46;"
                "apellidos" => "Fust&#224;-Novell"
              ]
              3 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Alsina Gibert"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "es" => array:9 [
          "pii" => "S0001731017305604"
          "doi" => "10.1016/j.ad.2017.07.019"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "es"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017305604?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301628?idApp=UINPBA000044"
      "url" => "/15782190/0000010900000006/v1_201808010420/S1578219018301628/v1_201808010420/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S0001731017305598"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2017.09.011"
    "estado" => "S300"
    "fechaPublicacion" => "2018-07-01"
    "aid" => "1825"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2018;109:567-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 211
      "formatos" => array:2 [
        "HTML" => 136
        "PDF" => 75
      ]
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fico-cl&#237;nica</span>"
      "titulo" => "Enfermedad boca-mano-pie at&#237;pica ves&#237;culo-ampollosa en 2 adultos"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "567"
          "paginaFinal" => "569"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Atypical Vesicular-Bullous Hand-Foot-Mouth Disease in 2 Adults"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1736
              "Ancho" => 1867
              "Tamanyo" => 642826
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Presentaci&#243;n cl&#237;nica correspondiente al caso 1&#58; a&#41; Costras melic&#233;ricas en regi&#243;n perioral&#59; b&#41; M&#225;culas eritematosas plantares&#46; Presentaci&#243;n cl&#237;nica correspondiente al caso 2&#59; c&#41; P&#225;pulas eritematosas en dorso de manos&#59; d&#41; P&#225;pulas eritematosas aisladas y confluentes en regi&#243;n distal del dorso de ambos pies&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "&#193;&#46; Iglesias-Puzas, A&#46; Batalla, M&#46; Trigo, &#193;&#46; Fl&#243;rez"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "&#193;&#46;"
              "apellidos" => "Iglesias-Puzas"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Batalla"
            ]
            2 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Trigo"
            ]
            3 => array:2 [
              "nombre" => "&#193;&#46;"
              "apellidos" => "Fl&#243;rez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219018301835"
        "doi" => "10.1016/j.adengl.2018.05.023"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301835?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017305598?idApp=UINPBA000044"
    "url" => "/00017310/0000010900000006/v1_201808010427/S0001731017305598/v1_201808010427/es/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S0001731017305628"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2017.07.020"
    "estado" => "S300"
    "fechaPublicacion" => "2018-07-01"
    "aid" => "1828"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2018;109:562-4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 54
      "formatos" => array:2 [
        "HTML" => 35
        "PDF" => 19
      ]
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fico-cl&#237;nica</span>"
      "titulo" => "Mucormicosis cut&#225;nea primaria por <span class="elsevierStyleItalic">Rhizopus arrhizus</span> en una ni&#241;a de 8 a&#241;os"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "562"
          "paginaFinal" => "564"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Primary Cutaneous Mucormycosis Due to <span class="elsevierStyleItalic">Rhizopus arrhizus</span> in an 8-Year-Old Girl"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 888
              "Ancho" => 1733
              "Tamanyo" => 248336
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A&#46; P&#225;pulas y seudoves&#237;culas eritematosas y purp&#250;ricas dispuestas de manera difusa sobre una base eritematosa con un centro necr&#243;tico en el abdomen&#46; B&#46; Aspecto gris&#225;ceo y putrefacto de la grasa del tejido subcut&#225;neo durante el procedimiento de la biopsia profunda&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46;F&#46; Alb&#237;zuri-Prado, A&#46; S&#225;nchez-Orta, A&#46; Rodr&#237;guez-Bandera, M&#46; Feito-Rodr&#237;guez"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "M&#46;F&#46;"
              "apellidos" => "Alb&#237;zuri-Prado"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "S&#225;nchez-Orta"
            ]
            2 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Rodr&#237;guez-Bandera"
            ]
            3 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Feito-Rodr&#237;guez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219018301811"
        "doi" => "10.1016/j.adengl.2018.05.021"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301811?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017305628?idApp=UINPBA000044"
    "url" => "/00017310/0000010900000006/v1_201808010427/S0001731017305628/v1_201808010427/es/main.assets"
  ]
  "es" => array:15 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fico-cl&#237;nica</span>"
    "titulo" => "Respuesta a secukinumab tras fracaso terap&#233;utico con ustekinumab en seis pacientes con psoriasis en placas"
    "tieneTextoCompleto" => true
    "saludo" => "<span class="elsevierStyleItalic">Sra&#46; Directora&#58;</span>"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "565"
        "paginaFinal" => "567"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "D&#46; Morgado-Carrasco, J&#46; Riera-Monroig, X&#46; Fust&#224;-Novell, M&#46; Alsina Gibert"
        "autores" => array:4 [
          0 => array:2 [
            "nombre" => "D&#46;"
            "apellidos" => "Morgado-Carrasco"
          ]
          1 => array:2 [
            "nombre" => "J&#46;"
            "apellidos" => "Riera-Monroig"
          ]
          2 => array:2 [
            "nombre" => "X&#46;"
            "apellidos" => "Fust&#224;-Novell"
          ]
          3 => array:4 [
            "nombre" => "M&#46;"
            "apellidos" => "Alsina Gibert"
            "email" => array:1 [
              0 => "malsina&#64;clinic&#46;cat"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Cl&#237;nic de Barcelona&#44; Universitat de Barcelona&#44; Barcelona&#44; Espa&#241;a"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 821
            "Ancho" => 2168
            "Tamanyo" => 119201
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Respuesta a tratamiento con secukinumab en pacientes con fracaso terap&#233;utico a ustekinumab&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">PASI&#58; <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span>&#59; SEC&#58; secukinumab&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Secukinumab &#40;SEC&#41; y ustekinumab &#40;UST&#41; son anticuerpos monoclonales altamente efectivos en el tratamiento de la psoriasis<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">1</span></a>&#44; aunque en los estudios pivotales SEC presenta mayores tasas de eficacia<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">2</span></a>&#46; Su mecanismo de acci&#243;n difiere en la diana inhibida de la cascada inflamatoria&#46; SEC bloquea la interleucina &#40;IL&#41;-17&#44; mientras que UST bloquea IL-12 e IL-23&#46; Los ensayos cl&#237;nicos han mostrado la efectividad de SEC en pacientes previamente tratados con otros f&#225;rmacos sist&#233;micos&#44; incluidos los anticuerpos monoclonales anti-TNF<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">3</span></a>&#46; Sin embargo&#44; hasta la fecha no existen publicaciones de su efectividad tras el fracaso terap&#233;utico con UST&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">En este trabajo nos propusimos evaluar la eficacia de SEC en pacientes con fracaso terap&#233;utico primario o secundario a UST&#44; definido como no alcanzar una reducci&#243;n del 75&#37; del <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span> &#40;PASI&#41; basal en la semana 12 o la p&#233;rdida de esta respuesta en las semanas siguientes&#44; respectivamente&#46; El objetivo primario fue evaluar en los pacientes tratados con SEC la obtenci&#243;n de la respuesta terap&#233;utica PASI90 &#40;reducci&#243;n del 90&#37; del PASI basal&#41;&#44; la obtenci&#243;n de un <span class="elsevierStyleItalic">Physician Global Assessment</span> &#40;PGA&#41; menor o igual a 1 &#40;ausente o m&#237;nimo&#41; y un <span class="elsevierStyleItalic">Dermatology Life Quality Index</span> &#40;DLQI&#41; menor o igual a 5 en la semana 12&#46; El objetivo secundario fue evaluar si esta respuesta se manten&#237;a en la semana 24&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Se evaluaron retrospectivamente seis pacientes con psoriasis en placas sin adecuada respuesta al tratamiento previo con UST y que fueron tratados con SEC seg&#250;n ficha t&#233;cnica &#40;inducci&#243;n completa y mantenimiento con 300<span class="elsevierStyleHsp" style=""></span>mg&#47;4<span class="elsevierStyleHsp" style=""></span>semanas&#41;&#46; Se midieron el PASI&#44; el PGA y el DLQI basal y en las semanas 12 y 24&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Las caracter&#237;sticas cl&#237;nico-epidemiol&#243;gicas se describen en la <a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#46; Se trata de seis pacientes varones de entre 32 y 61<span class="elsevierStyleHsp" style=""></span>a&#241;os de edad &#40;mediana 51<span class="elsevierStyleHsp" style=""></span>a&#241;os&#41; con psoriasis de m&#225;s de 10<span class="elsevierStyleHsp" style=""></span>a&#241;os de evoluci&#243;n &#40;mediana 16<span class="elsevierStyleHsp" style=""></span>a&#241;os&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">En la <a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a> se recoge la respuesta a tratamiento con UST y SEC&#46; Cuatro pacientes presentaron fallo primario a UST y dos&#44; fallo secundario&#46; Previo al inicio de SEC&#44; el PASI variaba entre 3&#44;2 y 21 &#40;mediana 12&#44;6&#41;&#44; el PGA entre 3 y 4 &#40;mediana 3&#41; y el DLQI entre 2 y 25 &#40;mediana 13&#44;5&#41;&#46; No se realiz&#243; tratamiento concomitante a la administraci&#243;n de SEC&#46; Todos los pacientes presentaron una reducci&#243;n de la actividad de la enfermedad a la semana 12 &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#44; con PASI90 en el 66&#44;7&#37; &#40;4&#47;6&#41;&#44; PGA y DLQI &#8804;<span class="elsevierStyleHsp" style=""></span>1 en el 83&#44;3&#37; &#40;5&#47;6&#41;&#46; En un paciente se suspendi&#243; SEC por no alcanzar el PASI50&#46; A la semana 24&#44; el 33&#44;3&#37; &#40;2&#47;6&#41; de los pacientes alcanz&#243; el PASI90&#44; el 66&#44;6&#37; &#40;4&#47;6&#41; logr&#243; el PASI75&#44; el 50&#37; &#40;3&#47;6&#41; ten&#237;a un PASI absoluto menor a 3 y el 66&#44;6&#37; &#40;4&#47;6&#41;&#44; un PGA y DLQI &#8804;<span class="elsevierStyleHsp" style=""></span>1&#46; No se observaron efectos adversos significativos durante las 24 semanas de tratamiento con SEC&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">En esta serie de seis pacientes con fracaso terap&#233;utico a UST se logr&#243; el objetivo primario con SEC en cuatro de ellos a la semana 12&#44; y el objetivo secundario en solo dos pacientes a la semana 24&#44; utilizando PASI90 como marcador de respuesta &#40;siguiendo la tendencia actual hacia resultados m&#225;s exigentes con los nuevos tratamientos biol&#243;gicos&#41;&#46; Sin embargo&#44; la mayor&#237;a alcanz&#243; el PASI75 y un PGA &#8804;<span class="elsevierStyleHsp" style=""></span>1 a las semanas 12 y 24&#44; siendo relevante la mejor&#237;a en la calidad de vida referida por los pacientes&#44; con una reducci&#243;n del DLQI en pr&#225;cticamente la totalidad de ellos&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Los resultados obtenidos con SEC son inferiores a los publicados en estudios pivotales<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">2&#44;3</span></a>&#44; lo cual puede deberse a que en nuestro estudio se incluyeron pacientes con fracaso a m&#250;ltiples tratamientos sist&#233;micos previos&#44; por lo que su enfermedad puede considerarse de dif&#237;cil manejo&#46; Otra explicaci&#243;n se basa en el mecanismo de acci&#243;n&#44; ya que UST&#44; a trav&#233;s de la inhibici&#243;n de la IL-23&#44; inhibe indirectamente a la IL-17<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">4</span></a>&#46; Por lo tanto&#44; los pacientes con fallo terap&#233;utico a UST ya hab&#237;an experimentado un cierto bloqueo de esta IL proinflamatoria &#40;diana de SEC&#41; sin obtener una respuesta cl&#237;nica adecuada&#46; Para avalar esta hip&#243;tesis&#44; ser&#237;a importante conocer la respuesta a SEC en pacientes con fracaso terap&#233;utico a anti-TNF&#44; f&#225;rmacos que no inhiben la IL-17&#46; Sin embargo&#44; no hemos encontrado publicaciones que aborden esta situaci&#243;n cl&#237;nica&#46; En los ensayos cl&#237;nicos pivotales de SEC&#44; menos del 10&#37; de los pacientes hab&#237;an presentado previamente fracaso terap&#233;utico a anti-TNF<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">2&#44;3</span></a>&#44; y lamentablemente no se realiz&#243; un an&#225;lisis de este subgrupo&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Por &#250;ltimo&#44; no hemos identificado factores pron&#243;sticos de respuesta terap&#233;utica a SEC tras el fracaso con UST&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">Las principales fortalezas de este trabajo son la utilizaci&#243;n de m&#250;ltiples criterios de respuesta cl&#237;nica &#40;PASI&#44; PGA y DLQI&#41; previo y durante la terapia biol&#243;gica&#44; as&#237; como un seguimiento de la respuesta hasta las 24 semanas&#44; y las principales limitaciones son su car&#225;cter retrospectivo y el peque&#241;o n&#250;mero de pacientes incluidos&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">En conclusi&#243;n&#44; SEC puede ser una alternativa terap&#233;utica en pacientes con fallo al tratamiento a UST&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicto de intereses</span><p id="par0055" class="elsevierStylePara elsevierViewall">Los autores declaran no tener ning&#250;n conflicto de intereses relacionado con este trabajo&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:2 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Conflicto de intereses"
        ]
        1 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:3 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 821
            "Ancho" => 2168
            "Tamanyo" => 119201
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Respuesta a tratamiento con secukinumab en pacientes con fracaso terap&#233;utico a ustekinumab&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">PASI&#58; <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span>&#59; SEC&#58; secukinumab&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">ACT&#58; acitretino&#59; anti-TNF&#58; anticuerpo monoclonal contra el factor de necrosis tumoral alfa&#59; CIC&#58; ciclosporina&#59; H&#58; hombre&#59; MTX&#58; metotrexato&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sexo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Edad &#40;a&#241;os&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Peso &#40;kg&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IMC &#40;kg&#47;m<span class="elsevierStyleSup">2</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Tabaquismo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">A&#241;os con psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Artritis psori&#225;sica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Comorbilidades&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Tratamientos sist&#233;micos previos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">107&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">32&#44;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">26&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Colitis microsc&#243;pica&#44; enfermedad pulmonar obstructiva cr&#243;nica&#44; hipertensi&#243;n arterial&#44; insuficiencia card&#237;aca&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CIC&#44; MTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">61&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">90&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">29&#44;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CIC&#44; MTX&#44; ACT&#44; anti-TNF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">58&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">61&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Hipertensi&#243;n arterial&#44; osteoporosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Leflunomida&#44; anti-TNF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">56&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">85&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">28&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CIC&#44; MTX&#44; ACT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">32&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">93&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30&#44;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">MTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">35&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">75&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25&#44;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Asma bronquial&#44; v&#233;rtigo posicional parox&#237;stico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CIC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1819499.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas cl&#237;nico-epidemiol&#243;gicas de los pacientes</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">DLQI&#58; <span class="elsevierStyleItalic">Dermatology Life Quality Index</span>&#59; NT&#58; tratamiento suspendido por falta de respuesta &#40;no alcanz&#243; el PASI50 en la semana 12&#41;&#59; PASI&#58; <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span>&#59; PGA&#58; <span class="elsevierStyleItalic">physician global assessment</span>&#59; SEC&#58; secukinumab&#59; UST&#58; ustekinumab&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Tratamiento con UST</th><th class="td" title="table-head  " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Previo inicio SEC</th><th class="td" title="table-head  " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">SEC semana 12</th><th class="td" title="table-head  " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">SEC semana 24</th></tr><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI previo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI semana 12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Fallo a UST&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">DLQI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PGA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI90&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">DLQI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PGA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI90&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">DLQI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PGA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">39&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11&#44;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Primario<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">22&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">43&#44;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">9&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Secundario<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">&#42;&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11&#44;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">9&#44;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">9&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8&#44;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Primario<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">16&#44;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">22&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Secundario<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">&#42;&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13&#44;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&#44;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Primario<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">3&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Primario<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1819500.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Fallo primario&#58; no alcanzar una reducci&#243;n del 75&#37; del PASI basal &#40;PASI75&#41; en la semana 12&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Fallo secundario&#58; disminuci&#243;n de la respuesta por debajo de PASI75 en las semanas siguientes&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Respuesta a secukinumab en pacientes con psoriasis en placas tras fracaso terap&#233;utico con ustekinumab</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:4 [
            0 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis&#58; A systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; Nast"
                            1 => "A&#46; Jacobs"
                            2 => "S&#46; Rosumeck"
                            3 => "R&#46;N&#46; Werner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/jid.2015.206"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Invest Dermatol&#46;"
                        "fecha" => "2015"
                        "volumen" => "135"
                        "paginaInicial" => "2641"
                        "paginaFinal" => "2648"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26046458"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis&#58; CLEAR&#44; a randomized controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Tha&#231;i"
                            1 => "A&#46; Blauvelt"
                            2 => "K&#46; Reich"
                            3 => "T&#46;-F&#46; Tsai"
                            4 => "F&#46; Vanaclocha"
                            5 => "K&#46; Kingo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2015.05.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2015"
                        "volumen" => "73"
                        "paginaInicial" => "400"
                        "paginaFinal" => "409"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26092291"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Secukinumab in plaque psoriasis &#8212; results of two phase 3 trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;G&#46; Langley"
                            1 => "B&#46;E&#46; Elewski"
                            2 => "M&#46; Lebwohl"
                            3 => "K&#46; Reich"
                            4 => "C&#46;E&#46;M&#46; Griffiths"
                            5 => "K&#46; Papp"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1314258"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med&#46;"
                        "fecha" => "2014"
                        "volumen" => "371"
                        "paginaInicial" => "326"
                        "paginaFinal" => "338"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25007392"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The IL-23-IL-17 immune axis&#58; From mechanisms to therapeutic testing"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46;L&#46; Gaffen"
                            1 => "R&#46; Jain"
                            2 => "A&#46;V&#46; Garg"
                            3 => "D&#46;J&#46; Cua"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/nri3707"
                      "Revista" => array:7 [
                        "tituloSerie" => "Nat Rev Immunol&#46;"
                        "fecha" => "2014"
                        "volumen" => "14"
                        "paginaInicial" => "585"
                        "paginaFinal" => "600"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25145755"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S000399931600040X"
                          "estado" => "S300"
                          "issn" => "00039993"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000010900000006/v1_201808010427/S0001731017305604/v1_201808010427/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6160"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Cartas cient&#237;fico-cl&#237;nicas"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000010900000006/v1_201808010427/S0001731017305604/v1_201808010427/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017305604?idApp=UINPBA000044"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Carta científico-clínica
Respuesta a secukinumab tras fracaso terapéutico con ustekinumab en seis pacientes con psoriasis en placas
Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis
D. Morgado-Carrasco, J. Riera-Monroig, X. Fustà-Novell, M. Alsina Gibert
Autor para correspondencia
malsina@clinic.cat

Autor para correspondencia.
Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, España
Leído
5350
Veces
se ha leído el artículo
1917
Total PDF
3433
Total HTML
Compartir estadísticas
 array:24 [
  "pii" => "S0001731017305604"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2017.07.019"
  "estado" => "S300"
  "fechaPublicacion" => "2018-07-01"
  "aid" => "1826"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2017"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "crp"
  "cita" => "Actas Dermosifiliogr. 2018;109:565-7"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 83
    "formatos" => array:2 [
      "HTML" => 43
      "PDF" => 40
    ]
  ]
  "Traduccion" => array:1 [
    "en" => array:19 [
      "pii" => "S1578219018301628"
      "issn" => "15782190"
      "doi" => "10.1016/j.adengl.2018.05.005"
      "estado" => "S300"
      "fechaPublicacion" => "2018-07-01"
      "aid" => "1826"
      "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
      "documento" => "simple-article"
      "crossmark" => 1
      "subdocumento" => "crp"
      "cita" => "Actas Dermosifiliogr. 2018;109:565-7"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 14
        "formatos" => array:2 [
          "HTML" => 8
          "PDF" => 6
        ]
      ]
      "en" => array:11 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>"
        "titulo" => "Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "565"
            "paginaFinal" => "567"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Respuesta a secukinumab tras fracaso terap&#233;utico con ustekinumab en seis pacientes con psoriasis en placas"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figure 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 828
                "Ancho" => 2185
                "Tamanyo" => 151810
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Response to treatment with secukinumab in patients with an unacceptable response to treatment with ustekinumab&#46;PASI&#44; Psoriasis Area and Severity Index&#59; SEC&#44; secukinumab&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "D&#46; Morgado-Carrasco, J&#46; Riera-Monroig, X&#46; Fust&#224;-Novell, M&#46; Alsina Gibert"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Morgado-Carrasco"
              ]
              1 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Riera-Monroig"
              ]
              2 => array:2 [
                "nombre" => "X&#46;"
                "apellidos" => "Fust&#224;-Novell"
              ]
              3 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Alsina Gibert"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "es" => array:9 [
          "pii" => "S0001731017305604"
          "doi" => "10.1016/j.ad.2017.07.019"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "es"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017305604?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301628?idApp=UINPBA000044"
      "url" => "/15782190/0000010900000006/v1_201808010420/S1578219018301628/v1_201808010420/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S0001731017305598"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2017.09.011"
    "estado" => "S300"
    "fechaPublicacion" => "2018-07-01"
    "aid" => "1825"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2018;109:567-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 211
      "formatos" => array:2 [
        "HTML" => 136
        "PDF" => 75
      ]
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fico-cl&#237;nica</span>"
      "titulo" => "Enfermedad boca-mano-pie at&#237;pica ves&#237;culo-ampollosa en 2 adultos"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "567"
          "paginaFinal" => "569"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Atypical Vesicular-Bullous Hand-Foot-Mouth Disease in 2 Adults"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1736
              "Ancho" => 1867
              "Tamanyo" => 642826
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Presentaci&#243;n cl&#237;nica correspondiente al caso 1&#58; a&#41; Costras melic&#233;ricas en regi&#243;n perioral&#59; b&#41; M&#225;culas eritematosas plantares&#46; Presentaci&#243;n cl&#237;nica correspondiente al caso 2&#59; c&#41; P&#225;pulas eritematosas en dorso de manos&#59; d&#41; P&#225;pulas eritematosas aisladas y confluentes en regi&#243;n distal del dorso de ambos pies&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "&#193;&#46; Iglesias-Puzas, A&#46; Batalla, M&#46; Trigo, &#193;&#46; Fl&#243;rez"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "&#193;&#46;"
              "apellidos" => "Iglesias-Puzas"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Batalla"
            ]
            2 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Trigo"
            ]
            3 => array:2 [
              "nombre" => "&#193;&#46;"
              "apellidos" => "Fl&#243;rez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219018301835"
        "doi" => "10.1016/j.adengl.2018.05.023"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301835?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017305598?idApp=UINPBA000044"
    "url" => "/00017310/0000010900000006/v1_201808010427/S0001731017305598/v1_201808010427/es/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S0001731017305628"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2017.07.020"
    "estado" => "S300"
    "fechaPublicacion" => "2018-07-01"
    "aid" => "1828"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2018;109:562-4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 54
      "formatos" => array:2 [
        "HTML" => 35
        "PDF" => 19
      ]
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fico-cl&#237;nica</span>"
      "titulo" => "Mucormicosis cut&#225;nea primaria por <span class="elsevierStyleItalic">Rhizopus arrhizus</span> en una ni&#241;a de 8 a&#241;os"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "562"
          "paginaFinal" => "564"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Primary Cutaneous Mucormycosis Due to <span class="elsevierStyleItalic">Rhizopus arrhizus</span> in an 8-Year-Old Girl"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 888
              "Ancho" => 1733
              "Tamanyo" => 248336
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A&#46; P&#225;pulas y seudoves&#237;culas eritematosas y purp&#250;ricas dispuestas de manera difusa sobre una base eritematosa con un centro necr&#243;tico en el abdomen&#46; B&#46; Aspecto gris&#225;ceo y putrefacto de la grasa del tejido subcut&#225;neo durante el procedimiento de la biopsia profunda&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46;F&#46; Alb&#237;zuri-Prado, A&#46; S&#225;nchez-Orta, A&#46; Rodr&#237;guez-Bandera, M&#46; Feito-Rodr&#237;guez"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "M&#46;F&#46;"
              "apellidos" => "Alb&#237;zuri-Prado"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "S&#225;nchez-Orta"
            ]
            2 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Rodr&#237;guez-Bandera"
            ]
            3 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Feito-Rodr&#237;guez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219018301811"
        "doi" => "10.1016/j.adengl.2018.05.021"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018301811?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017305628?idApp=UINPBA000044"
    "url" => "/00017310/0000010900000006/v1_201808010427/S0001731017305628/v1_201808010427/es/main.assets"
  ]
  "es" => array:15 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fico-cl&#237;nica</span>"
    "titulo" => "Respuesta a secukinumab tras fracaso terap&#233;utico con ustekinumab en seis pacientes con psoriasis en placas"
    "tieneTextoCompleto" => true
    "saludo" => "<span class="elsevierStyleItalic">Sra&#46; Directora&#58;</span>"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "565"
        "paginaFinal" => "567"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "D&#46; Morgado-Carrasco, J&#46; Riera-Monroig, X&#46; Fust&#224;-Novell, M&#46; Alsina Gibert"
        "autores" => array:4 [
          0 => array:2 [
            "nombre" => "D&#46;"
            "apellidos" => "Morgado-Carrasco"
          ]
          1 => array:2 [
            "nombre" => "J&#46;"
            "apellidos" => "Riera-Monroig"
          ]
          2 => array:2 [
            "nombre" => "X&#46;"
            "apellidos" => "Fust&#224;-Novell"
          ]
          3 => array:4 [
            "nombre" => "M&#46;"
            "apellidos" => "Alsina Gibert"
            "email" => array:1 [
              0 => "malsina&#64;clinic&#46;cat"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Cl&#237;nic de Barcelona&#44; Universitat de Barcelona&#44; Barcelona&#44; Espa&#241;a"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 821
            "Ancho" => 2168
            "Tamanyo" => 119201
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Respuesta a tratamiento con secukinumab en pacientes con fracaso terap&#233;utico a ustekinumab&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">PASI&#58; <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span>&#59; SEC&#58; secukinumab&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Secukinumab &#40;SEC&#41; y ustekinumab &#40;UST&#41; son anticuerpos monoclonales altamente efectivos en el tratamiento de la psoriasis<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">1</span></a>&#44; aunque en los estudios pivotales SEC presenta mayores tasas de eficacia<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">2</span></a>&#46; Su mecanismo de acci&#243;n difiere en la diana inhibida de la cascada inflamatoria&#46; SEC bloquea la interleucina &#40;IL&#41;-17&#44; mientras que UST bloquea IL-12 e IL-23&#46; Los ensayos cl&#237;nicos han mostrado la efectividad de SEC en pacientes previamente tratados con otros f&#225;rmacos sist&#233;micos&#44; incluidos los anticuerpos monoclonales anti-TNF<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">3</span></a>&#46; Sin embargo&#44; hasta la fecha no existen publicaciones de su efectividad tras el fracaso terap&#233;utico con UST&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">En este trabajo nos propusimos evaluar la eficacia de SEC en pacientes con fracaso terap&#233;utico primario o secundario a UST&#44; definido como no alcanzar una reducci&#243;n del 75&#37; del <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span> &#40;PASI&#41; basal en la semana 12 o la p&#233;rdida de esta respuesta en las semanas siguientes&#44; respectivamente&#46; El objetivo primario fue evaluar en los pacientes tratados con SEC la obtenci&#243;n de la respuesta terap&#233;utica PASI90 &#40;reducci&#243;n del 90&#37; del PASI basal&#41;&#44; la obtenci&#243;n de un <span class="elsevierStyleItalic">Physician Global Assessment</span> &#40;PGA&#41; menor o igual a 1 &#40;ausente o m&#237;nimo&#41; y un <span class="elsevierStyleItalic">Dermatology Life Quality Index</span> &#40;DLQI&#41; menor o igual a 5 en la semana 12&#46; El objetivo secundario fue evaluar si esta respuesta se manten&#237;a en la semana 24&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Se evaluaron retrospectivamente seis pacientes con psoriasis en placas sin adecuada respuesta al tratamiento previo con UST y que fueron tratados con SEC seg&#250;n ficha t&#233;cnica &#40;inducci&#243;n completa y mantenimiento con 300<span class="elsevierStyleHsp" style=""></span>mg&#47;4<span class="elsevierStyleHsp" style=""></span>semanas&#41;&#46; Se midieron el PASI&#44; el PGA y el DLQI basal y en las semanas 12 y 24&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Las caracter&#237;sticas cl&#237;nico-epidemiol&#243;gicas se describen en la <a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#46; Se trata de seis pacientes varones de entre 32 y 61<span class="elsevierStyleHsp" style=""></span>a&#241;os de edad &#40;mediana 51<span class="elsevierStyleHsp" style=""></span>a&#241;os&#41; con psoriasis de m&#225;s de 10<span class="elsevierStyleHsp" style=""></span>a&#241;os de evoluci&#243;n &#40;mediana 16<span class="elsevierStyleHsp" style=""></span>a&#241;os&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">En la <a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a> se recoge la respuesta a tratamiento con UST y SEC&#46; Cuatro pacientes presentaron fallo primario a UST y dos&#44; fallo secundario&#46; Previo al inicio de SEC&#44; el PASI variaba entre 3&#44;2 y 21 &#40;mediana 12&#44;6&#41;&#44; el PGA entre 3 y 4 &#40;mediana 3&#41; y el DLQI entre 2 y 25 &#40;mediana 13&#44;5&#41;&#46; No se realiz&#243; tratamiento concomitante a la administraci&#243;n de SEC&#46; Todos los pacientes presentaron una reducci&#243;n de la actividad de la enfermedad a la semana 12 &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#44; con PASI90 en el 66&#44;7&#37; &#40;4&#47;6&#41;&#44; PGA y DLQI &#8804;<span class="elsevierStyleHsp" style=""></span>1 en el 83&#44;3&#37; &#40;5&#47;6&#41;&#46; En un paciente se suspendi&#243; SEC por no alcanzar el PASI50&#46; A la semana 24&#44; el 33&#44;3&#37; &#40;2&#47;6&#41; de los pacientes alcanz&#243; el PASI90&#44; el 66&#44;6&#37; &#40;4&#47;6&#41; logr&#243; el PASI75&#44; el 50&#37; &#40;3&#47;6&#41; ten&#237;a un PASI absoluto menor a 3 y el 66&#44;6&#37; &#40;4&#47;6&#41;&#44; un PGA y DLQI &#8804;<span class="elsevierStyleHsp" style=""></span>1&#46; No se observaron efectos adversos significativos durante las 24 semanas de tratamiento con SEC&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">En esta serie de seis pacientes con fracaso terap&#233;utico a UST se logr&#243; el objetivo primario con SEC en cuatro de ellos a la semana 12&#44; y el objetivo secundario en solo dos pacientes a la semana 24&#44; utilizando PASI90 como marcador de respuesta &#40;siguiendo la tendencia actual hacia resultados m&#225;s exigentes con los nuevos tratamientos biol&#243;gicos&#41;&#46; Sin embargo&#44; la mayor&#237;a alcanz&#243; el PASI75 y un PGA &#8804;<span class="elsevierStyleHsp" style=""></span>1 a las semanas 12 y 24&#44; siendo relevante la mejor&#237;a en la calidad de vida referida por los pacientes&#44; con una reducci&#243;n del DLQI en pr&#225;cticamente la totalidad de ellos&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Los resultados obtenidos con SEC son inferiores a los publicados en estudios pivotales<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">2&#44;3</span></a>&#44; lo cual puede deberse a que en nuestro estudio se incluyeron pacientes con fracaso a m&#250;ltiples tratamientos sist&#233;micos previos&#44; por lo que su enfermedad puede considerarse de dif&#237;cil manejo&#46; Otra explicaci&#243;n se basa en el mecanismo de acci&#243;n&#44; ya que UST&#44; a trav&#233;s de la inhibici&#243;n de la IL-23&#44; inhibe indirectamente a la IL-17<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">4</span></a>&#46; Por lo tanto&#44; los pacientes con fallo terap&#233;utico a UST ya hab&#237;an experimentado un cierto bloqueo de esta IL proinflamatoria &#40;diana de SEC&#41; sin obtener una respuesta cl&#237;nica adecuada&#46; Para avalar esta hip&#243;tesis&#44; ser&#237;a importante conocer la respuesta a SEC en pacientes con fracaso terap&#233;utico a anti-TNF&#44; f&#225;rmacos que no inhiben la IL-17&#46; Sin embargo&#44; no hemos encontrado publicaciones que aborden esta situaci&#243;n cl&#237;nica&#46; En los ensayos cl&#237;nicos pivotales de SEC&#44; menos del 10&#37; de los pacientes hab&#237;an presentado previamente fracaso terap&#233;utico a anti-TNF<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">2&#44;3</span></a>&#44; y lamentablemente no se realiz&#243; un an&#225;lisis de este subgrupo&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Por &#250;ltimo&#44; no hemos identificado factores pron&#243;sticos de respuesta terap&#233;utica a SEC tras el fracaso con UST&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">Las principales fortalezas de este trabajo son la utilizaci&#243;n de m&#250;ltiples criterios de respuesta cl&#237;nica &#40;PASI&#44; PGA y DLQI&#41; previo y durante la terapia biol&#243;gica&#44; as&#237; como un seguimiento de la respuesta hasta las 24 semanas&#44; y las principales limitaciones son su car&#225;cter retrospectivo y el peque&#241;o n&#250;mero de pacientes incluidos&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">En conclusi&#243;n&#44; SEC puede ser una alternativa terap&#233;utica en pacientes con fallo al tratamiento a UST&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicto de intereses</span><p id="par0055" class="elsevierStylePara elsevierViewall">Los autores declaran no tener ning&#250;n conflicto de intereses relacionado con este trabajo&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:2 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Conflicto de intereses"
        ]
        1 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:3 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 821
            "Ancho" => 2168
            "Tamanyo" => 119201
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Respuesta a tratamiento con secukinumab en pacientes con fracaso terap&#233;utico a ustekinumab&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">PASI&#58; <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span>&#59; SEC&#58; secukinumab&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">ACT&#58; acitretino&#59; anti-TNF&#58; anticuerpo monoclonal contra el factor de necrosis tumoral alfa&#59; CIC&#58; ciclosporina&#59; H&#58; hombre&#59; MTX&#58; metotrexato&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sexo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Edad &#40;a&#241;os&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Peso &#40;kg&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IMC &#40;kg&#47;m<span class="elsevierStyleSup">2</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Tabaquismo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">A&#241;os con psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Artritis psori&#225;sica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Comorbilidades&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Tratamientos sist&#233;micos previos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">107&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">32&#44;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">26&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Colitis microsc&#243;pica&#44; enfermedad pulmonar obstructiva cr&#243;nica&#44; hipertensi&#243;n arterial&#44; insuficiencia card&#237;aca&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CIC&#44; MTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">61&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">90&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">29&#44;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CIC&#44; MTX&#44; ACT&#44; anti-TNF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">58&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">61&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Hipertensi&#243;n arterial&#44; osteoporosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Leflunomida&#44; anti-TNF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">56&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">85&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">28&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CIC&#44; MTX&#44; ACT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">32&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">93&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30&#44;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">MTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">H&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">35&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">75&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25&#44;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Asma bronquial&#44; v&#233;rtigo posicional parox&#237;stico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CIC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1819499.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas cl&#237;nico-epidemiol&#243;gicas de los pacientes</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">DLQI&#58; <span class="elsevierStyleItalic">Dermatology Life Quality Index</span>&#59; NT&#58; tratamiento suspendido por falta de respuesta &#40;no alcanz&#243; el PASI50 en la semana 12&#41;&#59; PASI&#58; <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span>&#59; PGA&#58; <span class="elsevierStyleItalic">physician global assessment</span>&#59; SEC&#58; secukinumab&#59; UST&#58; ustekinumab&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Tratamiento con UST</th><th class="td" title="table-head  " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Previo inicio SEC</th><th class="td" title="table-head  " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">SEC semana 12</th><th class="td" title="table-head  " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">SEC semana 24</th></tr><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI previo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI semana 12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Fallo a UST&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">DLQI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PGA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI90&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">DLQI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PGA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PASI90&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">DLQI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PGA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">39&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11&#44;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Primario<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">22&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">43&#44;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">9&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Secundario<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">&#42;&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11&#44;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">9&#44;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">9&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8&#44;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Primario<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">16&#44;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">22&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Secundario<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">&#42;&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13&#44;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&#44;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Primario<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">3&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Primario<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">S&#237;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1819500.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Fallo primario&#58; no alcanzar una reducci&#243;n del 75&#37; del PASI basal &#40;PASI75&#41; en la semana 12&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Fallo secundario&#58; disminuci&#243;n de la respuesta por debajo de PASI75 en las semanas siguientes&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Respuesta a secukinumab en pacientes con psoriasis en placas tras fracaso terap&#233;utico con ustekinumab</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:4 [
            0 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis&#58; A systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; Nast"
                            1 => "A&#46; Jacobs"
                            2 => "S&#46; Rosumeck"
                            3 => "R&#46;N&#46; Werner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/jid.2015.206"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Invest Dermatol&#46;"
                        "fecha" => "2015"
                        "volumen" => "135"
                        "paginaInicial" => "2641"
                        "paginaFinal" => "2648"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26046458"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis&#58; CLEAR&#44; a randomized controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Tha&#231;i"
                            1 => "A&#46; Blauvelt"
                            2 => "K&#46; Reich"
                            3 => "T&#46;-F&#46; Tsai"
                            4 => "F&#46; Vanaclocha"
                            5 => "K&#46; Kingo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2015.05.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2015"
                        "volumen" => "73"
                        "paginaInicial" => "400"
                        "paginaFinal" => "409"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26092291"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Secukinumab in plaque psoriasis &#8212; results of two phase 3 trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;G&#46; Langley"
                            1 => "B&#46;E&#46; Elewski"
                            2 => "M&#46; Lebwohl"
                            3 => "K&#46; Reich"
                            4 => "C&#46;E&#46;M&#46; Griffiths"
                            5 => "K&#46; Papp"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1314258"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med&#46;"
                        "fecha" => "2014"
                        "volumen" => "371"
                        "paginaInicial" => "326"
                        "paginaFinal" => "338"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25007392"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The IL-23-IL-17 immune axis&#58; From mechanisms to therapeutic testing"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46;L&#46; Gaffen"
                            1 => "R&#46; Jain"
                            2 => "A&#46;V&#46; Garg"
                            3 => "D&#46;J&#46; Cua"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/nri3707"
                      "Revista" => array:7 [
                        "tituloSerie" => "Nat Rev Immunol&#46;"
                        "fecha" => "2014"
                        "volumen" => "14"
                        "paginaInicial" => "585"
                        "paginaFinal" => "600"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25145755"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S000399931600040X"
                          "estado" => "S300"
                          "issn" => "00039993"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000010900000006/v1_201808010427/S0001731017305604/v1_201808010427/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6160"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Cartas cient&#237;fico-cl&#237;nicas"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000010900000006/v1_201808010427/S0001731017305604/v1_201808010427/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017305604?idApp=UINPBA000044"
]
Información del artículo
ISSN: 00017310
Idioma original: Español
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 9 11 20
2024 Octubre 81 42 123
2024 Septiembre 81 20 101
2024 Agosto 98 43 141
2024 Julio 106 24 130
2024 Junio 105 43 148
2024 Mayo 81 26 107
2024 Abril 103 24 127
2024 Marzo 77 31 108
2024 Febrero 76 23 99
2024 Enero 83 26 109
2023 Diciembre 60 15 75
2023 Noviembre 104 29 133
2023 Octubre 89 36 125
2023 Septiembre 87 30 117
2023 Agosto 62 15 77
2023 Julio 89 45 134
2023 Junio 74 26 100
2023 Mayo 73 25 98
2023 Abril 54 20 74
2023 Marzo 77 27 104
2023 Febrero 53 24 77
2023 Enero 41 27 68
2022 Diciembre 60 39 99
2022 Noviembre 97 40 137
2022 Octubre 88 53 141
2022 Septiembre 67 54 121
2022 Agosto 64 60 124
2022 Julio 51 62 113
2022 Junio 49 47 96
2022 Mayo 37 37 74
2022 Abril 41 28 69
2022 Marzo 60 58 118
2022 Febrero 44 33 77
2022 Enero 37 37 74
2021 Diciembre 39 31 70
2021 Noviembre 40 34 74
2021 Octubre 73 51 124
2021 Septiembre 38 36 74
2021 Agosto 28 25 53
2021 Julio 40 34 74
2021 Junio 60 33 93
2021 Mayo 46 43 89
2021 Abril 86 76 162
2021 Marzo 54 27 81
2021 Febrero 53 23 76
2021 Enero 29 22 51
2020 Diciembre 44 21 65
2020 Noviembre 35 27 62
2020 Octubre 24 24 48
2020 Septiembre 33 18 51
2020 Agosto 47 28 75
2020 Julio 39 21 60
2020 Junio 41 41 82
2020 Mayo 28 29 57
2020 Abril 28 24 52
2020 Marzo 25 25 50
2020 Febrero 2 4 6
2019 Diciembre 1 1 2
2019 Noviembre 19 0 19
2019 Octubre 1 0 1
2019 Septiembre 1 0 1
2019 Mayo 1 1 2
2019 Abril 2 2 4
2019 Marzo 1 2 3
2019 Febrero 1 0 1
2018 Diciembre 6 8 14
2018 Noviembre 3 2 5
2018 Septiembre 2 3 5
2018 Agosto 5 4 9
2018 Mayo 0 1 1
2018 Abril 0 2 2
2018 Marzo 0 1 1
2018 Febrero 0 2 2
2018 Enero 0 9 9
2017 Diciembre 0 2 2
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Actas Dermo-Sifiliográficas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?